Corvus Pharmaceuticals (CRVS) Competitors $7.00 +0.13 (+1.89%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$7.00 0.00 (0.00%) As of 10/8/2025 06:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRVS vs. VERA, TWST, ANIP, OCUL, DYN, APGE, TLRY, COGT, ABCL, and IMCRShould you be buying Corvus Pharmaceuticals stock or one of its competitors? The main competitors of Corvus Pharmaceuticals include Vera Therapeutics (VERA), Twist Bioscience (TWST), ANI Pharmaceuticals (ANIP), Ocular Therapeutix (OCUL), Dyne Therapeutics (DYN), Apogee Therapeutics (APGE), Tilray Brands (TLRY), Cogent Biosciences (COGT), AbCellera Biologics (ABCL), and Immunocore (IMCR). These companies are all part of the "pharmaceutical products" industry. Corvus Pharmaceuticals vs. Its Competitors Vera Therapeutics Twist Bioscience ANI Pharmaceuticals Ocular Therapeutix Dyne Therapeutics Apogee Therapeutics Tilray Brands Cogent Biosciences AbCellera Biologics Immunocore Corvus Pharmaceuticals (NASDAQ:CRVS) and Vera Therapeutics (NASDAQ:VERA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, media sentiment, dividends and valuation. Does the media refer more to CRVS or VERA? In the previous week, Corvus Pharmaceuticals had 1 more articles in the media than Vera Therapeutics. MarketBeat recorded 5 mentions for Corvus Pharmaceuticals and 4 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 1.66 beat Corvus Pharmaceuticals' score of 0.47 indicating that Vera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corvus Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vera Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has more volatility and risk, CRVS or VERA? Corvus Pharmaceuticals has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500. Comparatively, Vera Therapeutics has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500. Do analysts rate CRVS or VERA? Corvus Pharmaceuticals currently has a consensus target price of $13.00, indicating a potential upside of 85.71%. Vera Therapeutics has a consensus target price of $63.00, indicating a potential upside of 106.56%. Given Vera Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Vera Therapeutics is more favorable than Corvus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Corvus Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50Vera Therapeutics 1 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.60 Do insiders and institutionals believe in CRVS or VERA? 46.6% of Corvus Pharmaceuticals shares are held by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are held by institutional investors. 28.5% of Corvus Pharmaceuticals shares are held by company insiders. Comparatively, 16.3% of Vera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has stronger valuation and earnings, CRVS or VERA? Vera Therapeutics is trading at a lower price-to-earnings ratio than Corvus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCorvus PharmaceuticalsN/AN/A-$62.29M-$1.01-6.93Vera TherapeuticsN/AN/A-$152.15M-$3.58-8.52 Is CRVS or VERA more profitable? Corvus Pharmaceuticals' return on equity of -28.61% beat Vera Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Corvus PharmaceuticalsN/A -28.61% -18.05% Vera Therapeutics N/A -46.70%-39.46% SummaryCorvus Pharmaceuticals beats Vera Therapeutics on 7 of the 13 factors compared between the two stocks. Get Corvus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRVS vs. The Competition Export to ExcelMetricCorvus PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$511.91M$3.35B$6.10B$10.55BDividend YieldN/A2.28%5.69%4.75%P/E Ratio-6.9321.5785.6027.60Price / SalesN/A273.73538.21205.12Price / CashN/A47.1237.9261.55Price / Book13.7310.1413.246.76Net Income-$62.29M-$52.31M$3.30B$275.88M7 Day Performance-0.57%5.14%4.35%2.81%1 Month Performance13.45%14.68%9.51%9.24%1 Year Performance16.86%30.98%88.04%35.42% Corvus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRVSCorvus Pharmaceuticals1.8943 of 5 stars$7.00+1.9%$13.00+85.7%+17.8%$511.91MN/A-6.9330News CoverageAnalyst ForecastVERAVera Therapeutics2.7341 of 5 stars$31.34+1.3%$63.00+101.1%-21.1%$2.01BN/A-8.8040News CoveragePositive NewsAnalyst ForecastTWSTTwist Bioscience3.7451 of 5 stars$32.35+1.6%$48.90+51.1%-22.9%$1.99B$362.27M-22.72990Trending NewsAnalyst ForecastInsider TradeANIPANI Pharmaceuticals3.6261 of 5 stars$91.11-1.0%$97.29+6.8%+61.4%$1.97B$614.38M-117.89600Analyst DowngradeOCULOcular Therapeutix3.9647 of 5 stars$11.05+0.7%$22.13+100.3%+27.8%$1.93B$56.66M-8.65230Analyst ForecastInsider TradeDYNDyne Therapeutics3.5266 of 5 stars$13.10+3.6%$34.07+160.0%-56.1%$1.87BN/A-3.40100Analyst ForecastAPGEApogee Therapeutics3.2182 of 5 stars$39.67-0.5%$92.63+133.5%-15.8%$1.86BN/A-9.7491News CoverageAnalyst ForecastTLRYTilray Brands2.0469 of 5 stars$1.71+7.9%$1.94+13.6%+4.2%$1.85B$210.48M-0.732,842Trending NewsAnalyst ForecastCOGTCogent Biosciences2.8121 of 5 stars$15.89-0.1%$20.00+25.9%+43.6%$1.81BN/A-8.9480Analyst ForecastABCLAbCellera Biologics2.6471 of 5 stars$5.74-2.2%$8.00+39.4%+140.1%$1.72B$32.88M-10.44500Analyst ForecastIMCRImmunocore2.6213 of 5 stars$34.18-0.1%$56.89+66.4%+11.2%$1.71B$310.20M-84.91320Positive NewsAnalyst Forecast Related Companies and Tools Related Companies Vera Therapeutics Alternatives Twist Bioscience Alternatives ANI Pharmaceuticals Alternatives Ocular Therapeutix Alternatives Dyne Therapeutics Alternatives Apogee Therapeutics Alternatives Tilray Brands Alternatives Cogent Biosciences Alternatives AbCellera Biologics Alternatives Immunocore Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRVS) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corvus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corvus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
